(NP (NP (NN Abnormality)) (PP (IN of) (NP (NP (NN Oct-1) (NN DNA) (NN binding)) (PP (IN in) (NP (NP (NN T) (NNS cells)) (PP (IN from) (NP (NP (NN Sjogren) (POS 's)) (NN syndrome) (NNS patients))))))) (. .))
(S (NP-SBJ (JJ Primary) (NP (NP (NP (NN Sjogren) (POS 's)) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NN SS)) (-RRB- -RRB-)))) (VP (VBZ is) (NP-PRD (NP (DT an) (JJ autoimmune) (JJ rheumatic) (NN disease)) (VP (VBN characterized) (NP (-NONE- *)) (PP (IN by) (NP-LGS (NN T) (NN cell) (NN hypoactivity)))))) (. .))
(S (S (NP-SBJ-41 (-NONE- *-40)) (VP (TO To) (VP (VB understand) (NP (NP (DT the) (VBN diminished) (NN T) (NN cell) (NN response)) (PP (TO to) (NP (NN activation) (NNS signals))))))) (, ,) (NP-SBJ-40 (PRP we)) (VP (VBD measured) (NP (NP (NN nucleoprotein) (JJ DNA-binding) (NNS activities)) (VP (VBG regulating) (NP (NN gene) (NN expression)) (PP-TMP (IN during) (NP (NN T) (NN cell) (NN activation))))) (S (NP-SBJ (-NONE- *-41)) (VP (VBG using) (NP (DT the) (JJ electrophoretic) (NN mobility) (NN shift) (NN assay))))) (. .))
(S (NP-SBJ-42 (NP (JJ Peripheral) (NN blood) (NNS lymphocytes)) (PP (IN from) (NP (CD (19 9)) (NN SS) (NNS patients)))) (VP (VBD were) (VP (VBN found) (S (NP-SBJ (-NONE- *-42)) (VP (TO to) (VP (VB be) (ADJP-PRD (JJ defective)) (PP (IN in) (NP (PRP$ their) (NN ability) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB bind) (NP (NP (DT an) (NN october) (NN sequence)) (PRN (-LRB- -LRB-) (NP (NN Oct-1)) (-RRB- -RRB-))))))))))))) (. .))
(S (NP-SBJ (DT This) (JJ Oct-1-binding) (NN phenotype)) (VP (VBD remained) (ADJP-PRD (JJ stable)) (PP (IN in) (NP (NN culture))) (PP-TMP (IN for) (NP (NP (QP (IN up) (TO to) (CD 3)) (NNS days)) (PP-TMP (RB prior) (TO to) (NP (NN activation)))))) (. .))
(S (NP-SBJ-43 (DT This) (NN abnormality)) (VP (VBD was) (RB not) (VP (VBN seen) (NP (-NONE- *-43)) (PP (IN in) (NP (NP-COOD (NP (VBG resting) (NN T) (NNS cells)) (CC nor) (NP (NN T) (NNS cells))) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP-COOD (NP (JJ systemic) (NN lupus) (NN erythematosus)) (, ,) (NP (NP (JJ rheumatoid) (NN arthritis)) (PRN (-LRB- -LRB-) (NP (NN RA)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN SS)) (VP (VBN accompanied) (NP (-NONE- *)) (PP (IN by) (NP-LGS (NN RA))))))))))))) (. .))
(S (NP-SBJ (DT The) (NN SS) (NN Oct-1) (JJ DNA-binding) (NN abnormality)) (VP (VBD correlated) (ADVP (RB significantly)) (PP (IN with) (NP (NP (DT an) (NN inability) (S (-NONE- *ICH*-45))) (PP (IN of) (NP (NNS cells))) (S-45 (NP-SBJ-44 (-NONE- *)) (VP (TO to) (VP (VB exit) (NP (DT the) (NN (G1 Gzero)) (NN cell) (NN cycle) (NN phase)) (SBAR-TMP (WHADVP-46 (WRB when)) (S (NP-SBJ-47 (-NONE- *-44)) (VP (VBN stimulated) (NP (-NONE- *-47)) (ADVP (FW in) (FW vitro)) (ADVP (-NONE- *T*-46))))))))))) (. .))
(S (ADVP (RB Importantly)) (, ,) (NP-SBJ (NP (NN nucleoprotein) (NNS extracts)) (VP (VBG showing) (NP (VBN decreased) (JJ DNA-binding) (NN activity)))) (VP (VBD had) (NP (NP (JJ normal) (NNS amounts)) (PP (IN of) (NP (NN Oct-1) (NNS proteins))) (SBAR (IN as) (S (NP-SBJ-48 (-NONE- *)) (VP (VBN determined) (NP (-NONE- *-48)) (PP (IN by) (NP-LGS (NN immunoprecipitation))))))) (, ,) (S (NP-SBJ (-NONE- *)) (VP (VBG implying) (NP (NP (DT a) (JJ functional) (NN defect)) (PP (IN in) (NP (DT the) (NN Oct-1) (NN protein))))))) (. .))
(S (ADVP (RB Moreover)) (, ,) (NP-SBJ-49 (JJ defective) (NN DNA) (NN binding)) (VP (VBD was) (VP (VBN corrected) (NP (-NONE- *-49)) (PP (IN by) (NP-LGS (NP (NN treatment)) (PP (IN with) (NP (NN acid) (NN phosphatase))))))) (. .))
